SinoMab BioScience Limited Press Release

SinoMab's IND Application of SM17 has once again Received Approval from NAMP Sep 12, 2023 09:48 JST A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") More info..

SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP Aug 14, 2023 21:10 JST A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") More info..

SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE
Jun 12, 2023 20:43 JST

A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company")
More info..

SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE May 22, 2023 10:20 JST A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") More info..

SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards"
Dec 19, 2022 14:55 JST

SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases
More info..

SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company
Nov 04, 2022 17:47 JST

Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA
Aug 24, 2022 08:05 JST

SinoMab Received the Highest Subsidy from HKSTP Jul 08, 2022 19:03 JST SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-listed biopharmaceutical company dedicated to the research, development More info..

The Mechanism of Action of SinoMab's Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S.
Jun 21, 2022 15:38 JST

SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-listed biopharmaceutical company dedicated to the research, development
More info..

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.
Jun 15, 2022 13:03 JST

SinoMab Announces IND Application for SN1011 Accepted by NMPA CDE
Jun 09, 2022 12:48 JST

SinoMab BioScience Limited ("SinoMab"; 3681.HK), a Hong Kong-based biopharmaceutical company, an Investigational New Drug application (IND, for neuromyelitis optica spectrum disorder (NMOSD)) for SN1011 has been filed with and accepted by the Center for Drug Evaluation (the CDE) of the National Medical Products Administration of China (NMPA).
More info..

SinoMab Announces IND APPLICATION FOR SN1011 APPROVED BY NMPA Apr 20, 2022 19:33 JST SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development More info..

IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA
Mar 14, 2022 20:32 JST

IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA
Feb 17, 2022 15:13 JST

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE
Feb 07, 2022 18:05 JST

SinoMab Awarded the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies"
Jan 11, 2022 16:55 JST

SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03
Nov 30, 2021 20:50 JST

SinoMab BioScience Limited ("SinoMab", or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases
More info..

SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health
Nov 26, 2021 18:26 JST

SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases
Sep 17, 2021 08:40 JST

SinoMab BioScience Limited (HKEX 3681.HK, "SinoMab") announced with Suzhou Sinovent Pharmaceuticals Co., Ltd. ("Sinovent") today that they have entered into an exclusive licensing agreement with Everest Medicines (HKEX 1952.HK, "Everest")
More info..

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China
Jan 18, 2021 08:30 JST

SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the first healthy subject was successfully dosed in the Phase I clinical trial of SN1011
More info..

SinoMab Commenced Construction of its China Headquarters
Nov 23, 2020 15:20 JST

SinoMab entered into Strategic Collaboration with D2M Jul 23, 2020 07:20 JST SinoMab BioScience Limited ("SinoMab" of the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases More info..

SinoMab Announces Clinical Results on its First-in-target SM03 at EULAR 2020 Congress Jun 10, 2020 07:52 JST SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases More info..

SinoMab Granted the "Most Popular Newly Listed Company" Award
Jan 10, 2020 12:18 JST

SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the Group has won the title of the "Most Popular Newly Listed Company" at the 4th Hong Kong Golden Stocks Awards held in Shenzhen.
More info..

Great Potential in RA Therapeutic Market, Sinomab Announces Latest Progress of its Drug Candidate SM03 Phase III Clinical Trial for the Treatment RA
Nov 20, 2019 16:34 JST

SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce its latest progress of SM03 phase III clinical trial for the treatment rheumatoid arthritis.
More info..

SinoMab BioScience Announces Proposed Listing on the Main Board of SEHK Oct 30, 2019 18:50 JST SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development More info..